Avedro
General Information | |
Business: |
We are a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Our proprietary Avedro Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions, which are caused by changes in the shape of the eye that prevent light from focusing on the retina, causing blurred vision. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 122 |
Founded: | 2002 |
Contact Information | |
Address | 201 Jones Road, Waltham, MA 02451, US |
Phone Number | (781) 768-3400 |
Web Address | http://www.avedro.com |
View Prospectus: | Avedro |
Financial Information | |
Market Cap | $255.9mil |
Revenues | $24.0 mil (last 12 months) |
Net Income | $-25.4 mil (last 12 months) |
IPO Profile | |
Symbol | AVDR |
Exchange | NASDAQ |
Shares (millions): | 5.0 |
Price range | $14.00 - $14.00 |
Est. $ Volume | $70.0 mil |
Manager / Joint Managers | BofA Securities/ J.P. Morgan |
CO-Managers | Cowen and Company/ Guggenheim Securities/ SVB Leerink |
Expected To Trade: | 2/14/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |